HomeAI · summaries
Storia in 3 fonti
Sangamo’s three-decade run comes to a close as Lilly and Astellas eye assets
Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M, ending its run as a pioneer in gene editing.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Sangamo’s three-decade run comes to a close as Lilly and Astellas eye assets
Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M, ending its run as a pioneer in gene editing.
- ·
benzinga.com
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - SANGAMO THERAPEUT
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
- ·
biopharmadive.com
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA…